A trial found that Biogen Idec's experimental drug peginterferon beta-1a cut the annual rate of relapse by 36% compared with placebo in patients with multiple sclerosis when given every two weeks. The study of the injectable drug, which would be sold as Plegridy is approved, was presented at a meeting of the American Academy of Neurology.

Full Story:

Related Summaries